Akero Therapeutics (AKRO) to Release Earnings on Friday

Key Points

• Akero Therapeutics is set to announce its Q2 2025 earnings on August 8th, with analysts predicting a loss of ($0.95) per share.
• The company recently reported a positive quarterly earnings per share of $0.90, surpassing expectations by $1.91.
• Insider trading activity includes CEO Andrew Cheng selling 37,837 shares at an average price of $54.05, indicating a 6.37% decrease in his holdings.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. On average, analysts expect Akero Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Akero Therapeutics Stock Down 1.0%

Shares of Akero Therapeutics stock traded down $0.48 during trading on Friday, hitting $48.37. 867,371 shares of the stock traded hands, compared to its average volume of 872,309. The firm has a market cap of $3.86 billion, a P/E ratio of -24.81 and a beta of -0.28. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics has a 52-week low of $21.34 and a 52-week high of $58.40. The stock's fifty day simple moving average is $52.00 and its 200 day simple moving average is $45.80.

Analyst Ratings Changes

Several equities analysts have recently commented on AKRO shares. Bank of America raised their price target on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Citigroup dropped their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics currently has an average rating of "Buy" and an average target price of $82.50.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, insider Timothy Rolph sold 12,500 shares of the firm's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $51.09, for a total value of $638,625.00. Following the completion of the sale, the insider owned 167,124 shares of the company's stock, valued at approximately $8,538,365.16. This trade represents a 6.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Catriona Yale sold 10,000 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $52.95, for a total value of $529,500.00. Following the completion of the sale, the insider directly owned 91,488 shares of the company's stock, valued at approximately $4,844,289.60. This represents a 9.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 235,906 shares of company stock valued at $11,862,790 over the last 90 days. Company insiders own 7.07% of the company's stock.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors have recently added to or reduced their stakes in AKRO. Royal Bank of Canada raised its position in Akero Therapeutics by 14.0% during the first quarter. Royal Bank of Canada now owns 26,602 shares of the company's stock valued at $1,077,000 after acquiring an additional 3,263 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Akero Therapeutics by 15.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,818 shares of the company's stock valued at $1,943,000 after acquiring an additional 6,376 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Akero Therapeutics by 6.7% during the first quarter. Goldman Sachs Group Inc. now owns 488,392 shares of the company's stock valued at $19,770,000 after acquiring an additional 30,868 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Akero Therapeutics by 53.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company's stock valued at $4,449,000 after acquiring an additional 38,458 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.